The US Food and Drug Administration (FDA) is investigating possible secondary T-cell malignancies following chimeric antigen receptor T-cell (CAR-T) immunotherapy, the agency announced on Nov 28, 2023. 19 patients are involved.
[News] FDA investigates risk of secondary lymphomas after CAR-T immunotherapy
For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –
LATEST
Sign up for our emails
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Newsletter
Privacy Policy